Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Physiomics ( (GB:PYC) ) just unveiled an announcement.
Physiomics plc has announced a new contract with Numab Therapeutics to use PK/PD modelling and simulation for a First In Human study in Numab’s Inflammation pipeline. This collaboration represents a significant step in applying Model Informed Drug Development to support early clinical development, aligning with Physiomics’ mission to enhance decision-making and outcomes in drug development. The project is expected to begin imminently and conclude within six months, marking an expansion of Physiomics’ services beyond oncology.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a company specializing in mathematical modelling, data science, and biostatistics to support the development of new therapeutics and personalized medicine solutions. They combine expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to help biotech and pharma companies streamline their drug development processes. Physiomics has informed the development of over 100 commercial projects and has collaborated with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.
Average Trading Volume: 8,805,322
Technical Sentiment Signal: Sell
Current Market Cap: £1.44M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.